INOVIO PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Realized Loss
INOVIO PHARMACEUTICALS, INC. (INO) reported Debt Securities, Available-for-sale, Realized Loss of $574.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2026-06-30 was $574.00K, a 18.93% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2026-03-31 was $285.00K, a 40614.29% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2025-09-30 was $183.00K, a 68.82% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for fiscal 2025 was $892.00K, a 53.05% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for fiscal 2024 was $1.90M, a 60.42% decline from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for fiscal 2023 was $4.80M, a 17.07% increase from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. debt securities, available-for-sale, realized loss for fiscal 2022 was $4.10M, a 927.57% increase from fiscal 2021.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $574.00K 10-Q · filed 2026-08-12 | $859.00K 10-Q · filed 2026-08-12 | $859.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $285.00K 10-Q · filed 2026-05-13 | $285.00K derived: sum of 2 quarters · filed 2026-05-13 | $468.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $183.00K derived: sum of 2 quarters · filed 2026-03-12 | $891.00K derived: sum of 3 quarters · filed 2026-08-12 | $892.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $183.00K 10-Q · filed 2025-11-10 | $891.00K derived: sum of 2 quarters · filed 2026-08-12 | $892.00K 10-Q · filed 2025-11-10 | $1.49M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $708.00K 10-Q · filed 2026-08-12 | $709.00K 10-Q · filed 2026-08-12 | $1.31M derived: sum of 3 quarters · filed 2026-08-12 | $1.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $700.00 10-Q · filed 2026-05-13 | $600.70K derived: sum of 2 quarters · filed 2026-05-13 | $1.19M derived: sum of 3 quarters · filed 2026-05-13 | $1.19M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.19M derived: sum of 2 quarters · filed 2026-03-12 | $1.19M derived: sum of 3 quarters · filed 2026-03-12 | $1.90M 10-K · filed 2026-03-12 |
| 2024-09-30 | $587.00K 10-Q · filed 2025-11-10 | $589.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.30M 10-Q · filed 2025-11-10 | $2.18M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.00K 10-Q · filed 2025-08-12 | $693.00K 10-Q · filed 2025-08-12 | $1.59M derived: sum of 3 quarters · filed 2025-08-12 | $1.59M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $691.00K 10-Q · filed 2025-05-13 | $1.59M derived: sum of 2 quarters · filed 2025-05-13 | $1.59M derived: sum of 3 quarters · filed 2025-05-13 | $3.09M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $900.50K derived: sum of 2 quarters · filed 2025-03-18 | $2.40M derived: sum of 3 quarters · filed 2025-03-18 | $4.80M 10-K · filed 2025-03-18 |
| 2023-09-30 | $500.00 10-Q · filed 2024-11-14 | $1.50M derived: sum of 2 quarters · filed 2024-11-14 | $3.90M 10-Q · filed 2024-11-14 | $6.70M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.50M 10-Q · filed 2024-08-08 | $3.90M 10-Q · filed 2024-08-08 | $6.70M derived: sum of 3 quarters · filed 2024-08-08 | $7.64M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.40M 10-Q · filed 2024-05-13 | $5.20M derived: sum of 2 quarters · filed 2024-05-13 | $6.14M derived: sum of 3 quarters · filed 2024-05-13 | $6.15M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $3.75M derived: sum of 2 quarters · filed 2024-03-06 | $3.75M derived: sum of 3 quarters · filed 2024-03-06 | $4.10M 10-K · filed 2024-03-06 |
| 2022-09-30 | $945.00K 10-Q · filed 2023-11-09 | $948.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.30M 10-Q · filed 2023-11-09 | $1.42M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.00K 10-Q · filed 2023-08-09 | $342.00K 10-Q · filed 2023-08-09 | $479.00K derived: sum of 3 quarters · filed 2023-08-09 | $537.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $339.00K 10-Q · filed 2023-05-10 | $476.00K derived: sum of 2 quarters · filed 2023-05-10 | $534.00K derived: sum of 3 quarters · filed 2023-05-10 | $728.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $195.00K derived: sum of 2 quarters · filed 2023-03-01 | $389.00K derived: sum of 3 quarters · filed 2023-03-01 | $399.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $58.00K 10-Q · filed 2022-11-08 | $252.00K derived: sum of 2 quarters · filed 2022-11-08 | $262.00K 10-Q · filed 2022-11-08 | $262.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $194.00K 10-Q · filed 2022-08-09 | $204.00K 10-Q · filed 2022-08-09 | $204.00K derived: sum of 3 quarters · filed 2022-08-09 | $305.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-10 | $10.00K derived: sum of 2 quarters · filed 2022-05-10 | $111.00K derived: sum of 3 quarters · filed 2022-05-10 | $797.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $101.00K derived: sum of 2 quarters · filed 2022-03-01 | $787.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.30M 10-K · filed 2022-03-01 |
| 2020-09-30 | $101.00K 10-Q · filed 2021-11-09 | $787.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.30M 10-Q · filed 2021-11-09 | $1.34M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $686.00K 10-Q · filed 2021-08-09 | $1.20M 10-Q · filed 2021-08-09 | $1.24M derived: sum of 3 quarters · filed 2021-08-09 | $1.25M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $525.00K 10-Q · filed 2021-05-10 | $550.00K derived: sum of 2 quarters · filed 2021-05-10 | $561.00K derived: sum of 3 quarters · filed 2021-05-10 | $590.00K derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $36.00K derived: sum of 2 quarters · filed 2021-03-01 | $65.00K derived: sum of 3 quarters · filed 2021-03-01 | $118.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $11.00K 10-Q · filed 2020-11-09 | $40.00K derived: sum of 2 quarters · filed 2020-11-09 | $93.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $29.00K 10-Q · filed 2020-08-10 | $82.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $53.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $1.30M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |